Molecular Partners AGMLLCF 25 Cash Ratio is 8.95 as of Mar. 2026, which is 12% below its 10-year median of 10.22. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,387 Biotechnology companies, Molecular Partners AG ranks better than 77.51% on this metric.
Molecular Partners AG has a Cash Ratio of 8.95. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Molecular Partners AG's Cash Ratio or its related term are showing as below:
MLLCF'
s Cash Ratio Range Over the Past 10 Years
Min: 2.19 Med: 10.22 Max: 18.41
Current: 8.95
During the past 13 years, Molecular Partners AG's highest Cash Ratio was 18.41. The lowest was 2.19. And the median was 10.22.
MLLCF's Cash Ratio is ranked better than 77.51% of 1387
companies
in the Biotechnology industry
Industry Median: 2.93
vs MLLCF: 8.95
Molecular Partners AG (OTCPK:MLLCF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Molecular Partners AG's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (MLLCF) has a Cash Ratio of 8.95 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Molecular Partners AG and its competitors. This is 12% below median its historical median of 10.22. Over the past decade, Molecular Partners AG's Cash Ratio has ranged from 2.19 to 18.41. According to the industry distribution chart, Molecular Partners AG ranks #312 out of 1387 companies in the Biotechnology industry, placing it in the top 22.5%.
Is Molecular Partners AG's Cash Ratio too high?
Molecular Partners AG's current Cash Ratio of 8.95 is 12% below median its 10-year median of 10.22. Over the past 10 years, this metric has ranged from a low of 2.19 to a high of 18.41. The Biotechnology industry median Cash Ratio is 2.93. Molecular Partners AG's value of 8.95 is 205.5% above this industry median. Based on the distribution chart, Molecular Partners AG ranks #312 out of 1387 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #312 out of 1387 companies for Cash Ratio. This places Molecular Partners AG in the top 23% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Molecular Partners AG's value of 8.95 is 205.5% above this benchmark. Historically, Molecular Partners AG's own Cash Ratio has ranged from 2.19 to 18.41 over the past decade. While the company's 10-year median is 10.22 vs. the industry median of 2.93, Molecular Partners AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,387 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Molecular Partners AG's current Cash Ratio of 8.95 is 205.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Molecular Partners AG and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Cash Ratio is 8.95, which is 12% below median its own 10-year median of 10.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.42, compared to a current price of $3.60 — trading 757.1% above its estimated fair value. The current Cash Ratio is 8.95, which is 12% below median its 10-year median of 10.22 and 205.5% above the Biotechnology industry median of 2.93. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Cash Ratio is 8.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.60 is trading 757.1% above its estimated GF Value™ of $0.42.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
Cash Ratio: 8.95 (12% below median its 10-year median of 10.22)
GF Value™: $0.42 vs. price of $3.60 (757.1% above fair value)
Industry Position: 205.5% above the Biotechnology median (#312 of 1387)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score
Get the complete analysis for MLLCF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
